JP2024501831A5 - - Google Patents
Info
- Publication number
- JP2024501831A5 JP2024501831A5 JP2023538969A JP2023538969A JP2024501831A5 JP 2024501831 A5 JP2024501831 A5 JP 2024501831A5 JP 2023538969 A JP2023538969 A JP 2023538969A JP 2023538969 A JP2023538969 A JP 2023538969A JP 2024501831 A5 JP2024501831 A5 JP 2024501831A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129829P | 2020-12-23 | 2020-12-23 | |
| US63/129,829 | 2020-12-23 | ||
| US202163225821P | 2021-07-26 | 2021-07-26 | |
| US63/225,821 | 2021-07-26 | ||
| US202163250329P | 2021-09-30 | 2021-09-30 | |
| US63/250,329 | 2021-09-30 | ||
| US202163257345P | 2021-10-19 | 2021-10-19 | |
| US63/257,345 | 2021-10-19 | ||
| PCT/US2021/065069 WO2022140665A1 (en) | 2020-12-23 | 2021-12-23 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501831A JP2024501831A (ja) | 2024-01-16 |
| JP2024501831A5 true JP2024501831A5 (https=) | 2024-12-04 |
| JPWO2022140665A5 JPWO2022140665A5 (https=) | 2024-12-04 |
Family
ID=82160130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538969A Pending JP2024501831A (ja) | 2020-12-23 | 2021-12-23 | 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240117002A1 (https=) |
| EP (1) | EP4267733A4 (https=) |
| JP (1) | JP2024501831A (https=) |
| AU (1) | AU2021410788A1 (https=) |
| CA (1) | CA3203180A1 (https=) |
| WO (1) | WO2022140665A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240252641A1 (en) * | 2020-05-05 | 2024-08-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| AU2023338694A1 (en) * | 2022-09-08 | 2025-04-03 | Cugene Inc. | Novel pd1-targeted il-15 immunocytokine and vitokine fusions |
| AU2024269870A1 (en) * | 2023-05-05 | 2025-11-20 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107880136B (zh) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA3036745A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| US11851491B2 (en) * | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| EP3638295A1 (en) * | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20210015859A1 (en) * | 2017-12-08 | 2021-01-21 | Fate Therapeutics, Inc. | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CA3093449A1 (en) * | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| WO2020198033A1 (en) * | 2019-03-22 | 2020-10-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20230069322A1 (en) * | 2019-12-24 | 2023-03-02 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
| US20240252641A1 (en) * | 2020-05-05 | 2024-08-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
-
2021
- 2021-12-23 CA CA3203180A patent/CA3203180A1/en active Pending
- 2021-12-23 EP EP21912227.2A patent/EP4267733A4/en active Pending
- 2021-12-23 JP JP2023538969A patent/JP2024501831A/ja active Pending
- 2021-12-23 US US18/269,214 patent/US20240117002A1/en active Pending
- 2021-12-23 AU AU2021410788A patent/AU2021410788A1/en not_active Abandoned
- 2021-12-23 WO PCT/US2021/065069 patent/WO2022140665A1/en not_active Ceased